2018
Resection of retroperitoneal sarcoma en‐bloc with inferior vena cava: 20 year outcomes of a single institution
Blair AB, Reames BN, Singh J, Gani F, Overton HN, Beaulieu RJ, Lum YW, Black JH, Johnston FM, Ahuja N. Resection of retroperitoneal sarcoma en‐bloc with inferior vena cava: 20 year outcomes of a single institution. Journal Of Surgical Oncology 2018, 118: 127-137. PMID: 29878363, PMCID: PMC6220674, DOI: 10.1002/jso.25096.Peer-Reviewed Original Research
2017
Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis?
Dogeas E, Chong CCN, Weiss MJ, Ahuja N, Choti MA. Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis? Hepato Pancreato Biliary 2017, 20: 237-243. PMID: 29103839, DOI: 10.1016/j.hpb.2017.08.029.Peer-Reviewed Original ResearchConceptsNeuroendocrine liver metastasesTumor biologyLiver metastasesShorter median disease-free survivalMedian disease-free survivalDisease-free survivalManagement of patientsPotential prognostic factorsSmaller tumor sizeLong-term outcomesHypoechoic metastasesAdditional metastasesPrognostic factorsClinicopathologic factorsSurgical interventionSurgical strategyPreoperative imagingTumor sizeHypoechoic lesionsIntraoperative ultrasonographyNeuroendocrine tumorsProspective dataHyperechoic lesionsTumor gradeBiologic behavior
2016
Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL, Ahuja N. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget 2016, 5: 86480-86489. PMID: 27880934, PMCID: PMC5349928, DOI: 10.18632/oncotarget.13441.Peer-Reviewed Original ResearchConceptsDisease-free survivalStage II colorectal cancer patientsStage II CRC patientsCpG island methylator phenotypeMLH1 methylation statusColorectal cancer patientsOverall survivalLymphovascular invasionCRC patientsCancer patientsMucin productionMethylator phenotypeKaplan-Meier analysisPoor clinical outcomeMethylation statusDuodenal adenocarcinomaClinical outcomesAggressive featuresPoor prognosisPrognostic valuePatient subgroupsTumor locationMultivariate analysisPatientsM groupMethylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma
Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan W, Baylin SB, Wolfgang CL, Ahuja N. Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. PLOS ONE 2016, 11: e0162929. PMID: 27643594, PMCID: PMC5028050, DOI: 10.1371/journal.pone.0162929.Peer-Reviewed Original ResearchConceptsDisease-free survivalCpG island methylator phenotypeDuodenal adenocarcinomaOverall survivalMethylation of MGMTMGMT methylationMicrosatellite instabilityPoor prognosisKRAS mutationsCox proportional hazards modelMGMT unmethylated groupTumor molecular featuresChemotherapy/radiotherapyIndependent prognostic factorO6-methylguanine-DNA methyltransferase methylation statusWorse overall survivalPossible prognostic valueProportional hazards modelMGMT methylation statusPrognostic factorsClinicopathological characteristicsTumor characteristicsMethylation statusPrognostic valueTumor differentiation
2014
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis
Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Annals Of Oncology 2014, 25: 2314-2327. PMID: 24718889, PMCID: PMC4239805, DOI: 10.1093/annonc/mdu149.Peer-Reviewed Original ResearchConceptsDisease-free survivalCpG island methylator phenotypeColorectal cancer patientsCRC patientsOverall survivalHazard ratioPredictive factorsPrognostic valueCancer patientsPredictive valuePatient disease-free survivalShorter disease-free survivalCancer-specific mortalityAdditional survival benefitMethylator phenotypeShorter overall survivalMicrosatellite instability statusAdjuvant chemotherapyDFS benefitSurvival benefitWorse prognosisCRC prognosisPooled analysisSubgroup analysisNineteen studiesA Systematic Review of Solid-Pseudopapillary Neoplasms
Law JK, Ahmed A, Singh VK, Akshintala VS, Olson MT, Raman SP, Ali SZ, Fishman EK, Kamel I, Canto MI, Dal Molin M, Moran RA, Khashab MA, Ahuja N, Goggins M, Hruban RH, Wolfgang CL, Lennon AM. A Systematic Review of Solid-Pseudopapillary Neoplasms. Pancreas 2014, 43: 331-337. PMID: 24622060, PMCID: PMC4888067, DOI: 10.1097/mpa.0000000000000061.Peer-Reviewed Original ResearchConceptsSolid pseudopapillary neoplasmSystematic reviewExcellent long-term prognosisDisease-free survivalMainstay of treatmentMean tumor sizeLong-term prognosisAbdominal painNonspecific symptomsPancreatic resectionMedian timeCommon symptomsNeoplasm casesTumor sizeMean agePatientsNumber of casesYoung womenRecurrenceNeoplasmsSymptomsMonthsTotalPainResection
2012
Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients
Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG, Gamblin TC, Pawlik TM. Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients. Annals Of Surgical Oncology 2012, 19: 4036-4042. PMID: 22972507, PMCID: PMC3568525, DOI: 10.1245/s10434-012-2634-6.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalDesmoid tumorsTumor locationWorse recurrence-free survivalRare soft tissue neoplasmMajor surgical centersR0 surgical marginsDisease-free survivalEffective adjuvant therapyManagement of patientsPredictors of recurrenceRate of recurrenceMulti-institutional analysisSoft tissue neoplasmBackgroundDesmoid tumorsResultsMedian ageAdjuvant therapyMost patientsSurgical resectionMargin statusSurgical marginsSurgical centersTreatment characteristicsRecurrence patternsAbdominal cavityColorectal Cancer Stem Cells—Hype or Real?: Comment on “Combined CD133+/CD44+ Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer”
Ahuja N. Colorectal Cancer Stem Cells—Hype or Real?: Comment on “Combined CD133+/CD44+ Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer”. JAMA Surgery 2012, 147: 24-25. PMID: 22250107, DOI: 10.1001/archsurg.2011.1218.Peer-Reviewed Original Research